Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma (SAPPHIRE)

This study has been terminated.
(Stopped due to lack of patients (no safety or efficacy issues). Reasons: Changed WHO brain tumor definitions, standard of care 1st line, neurosurgical advances.)
Information provided by (Responsible Party):
Isarna Therapeutics GmbH
ClinicalTrials.gov Identifier:
First received: September 26, 2008
Last updated: October 22, 2013
Last verified: October 2013

September 26, 2008
October 22, 2013
December 2008
February 2012   (final data collection date for primary outcome measure)
Survival rate [ Time Frame: 24 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00761280 on ClinicalTrials.gov Archive Site
  • Progression rate [ Time Frame: 10, 12, 14, 16, 18, 21, and 24 months ] [ Designated as safety issue: No ]
  • Time to death (months) [ Designated as safety issue: No ]
  • Overall response rate [ Designated as safety issue: No ]
  • Tumor control rate [ Designated as safety issue: No ]
  • Duration of response [ Designated as safety issue: No ]
  • Time to progression (months) [ Designated as safety issue: No ]
  • Survival rate [ Time Frame: 12, 18, 21, 27, and 30 months; 3 and 4 years ] [ Designated as safety issue: No ]
  • Quality of Life (EORTC QLQ-C30, Independent Living Score [ILS]) [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.

In this multinational Phase III study the efficacy and safety of 10 µM AP 12009 is compared to standard chemotherapy (temozolomide or BCNU or CCNU) in adult patients with confirmed recurrent or refractory anaplastic astrocytoma (WHO grade III) or secondary glioblastoma (WHO grade IV).

The purpose of this study is to compare the safety and efficacy of the 10 µM concentration of AP 12009 and standard chemotherapy (temozolomide, BCNU, CCNU) in adult patients with recurrent or refractory anaplastic astrocytoma (AA, WHO grade III) or secondary glioblastoma (GBM, WHO grade IV). AP 12009 (trabedersen) is a phosphorothioate antisense oligodeoxynucleotide specific for the mRNA of human Transforming Growth Factor beta 2 (TGF-beta-2), which is applied intratumorally. The growth factor TGF-beta plays a key role in malignant progression of various tumors by inducing proliferation, invasion, metastasis, angiogenesis, and escape from immunosurveillance. In patients with high-grade glioma, the TGF-beta-2 overexpression is associated with disease stage, clinical prognosis, and the immunodeficient state of the patients. Main objective of the study is to determine survival (rate) and tumor response.

Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Anaplastic Astrocytoma
  • Glioblastoma
  • Drug: trabedersen
    Other Name: AP 12009
  • Drug: temozolomide
    Other Names:
    • Temodar
    • Temodal
    • TMZ
  • Device: Drug delivery system for administration of AP 12009
    Drug delivery system for Convection Enhanced Delivery consists of a portable pump (Pegasus vario or Pega vario) with drug reservoir (Pega Bag) and infusion line (Pega Line). Main implanted parts are the port access system (PORT-A-CATH) and the intratumoral catheter (Medtronic ventricular catheter).
  • Procedure: Placement of Drug Delivery System
    Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
  • Drug: carmustine
    Other Names:
    • BCNU
    • BiCNU
    • Carmubris
  • Drug: lomustine
    Other Names:
    • CCNU
    • CeeNU
  • Experimental: trabedersen 10 µM
    10 µM trabedersen (AP 12009), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
    • Drug: trabedersen
    • Device: Drug delivery system for administration of AP 12009
    • Procedure: Placement of Drug Delivery System
  • Active Comparator: Chemotherapy
    temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle, up to 26 cycles; carmustine: i.v. administration, up to 200 mg/sqm/day, 1 day per cycle, up to 8 cycles; lomustine: capsules, 110 mg/sqm/day, 1 day per cycle, up to 8 cycles. Only 1 of these 3 drugs/interventions is administered per patient in the comparator arm.
    • Drug: temozolomide
    • Drug: carmustine
    • Drug: lomustine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
June 2012
February 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The patient has provided written informed consent prior to any study-related procedure.
  • The patient is at least 18 years of age and equal to or below 70 years.
  • The patient has a present diagnosis of AA or secondary GBM.
  • The patient has a measurable lesion (> 1 ccm in volume, central MRI review).
  • The lesion (or sum of lesions) does not exceed 50 ccm in volume (central MRI review).
  • The tumor is localized supratentorially (central MRI review).
  • All patients have recurrent or refractory disease, i.e. disease has progressed after prior surgery and radiotherapy at any time of the disease course or stage. Secondary GBM patients have progressed after a previous diagnosis of A and/or AA.
  • The patient has not received more than one chemotherapy regimen. Radiation with concomitant chemotherapy, followed by adjuvant chemotherapy, is considered as one chemotherapy regimen.
  • The patient is eligible for chemotherapy.
  • The patient is on a maximum dose of 4 mg/day dexamethasone or equivalent doses for other corticosteroids, which has been stable or decreasing for at least 3 weeks prior to Screening.
  • The patient is male or a non-pregnant, non-lactating female.
  • Females of childbearing potential must have a negative beta-HCG pregnancy test at Screening.
  • Females of childbearing potential and males must practice strict birth control.
  • The patient must have recovered from acute toxicity caused by any previous therapy.
  • The patient has a life expectancy of at least 3 months.
  • The patient has a Karnofsky Performance Status of at least 70%.
  • The patient shows adequate organ functions as assessed by the following screening laboratory values:

    1. Adequate renal function determined by serum creatinine and urea < 2 times the upper limit of normal
    2. Adequate liver function with ALT, AST and AP < 3 times the upper limit of normal, and bilirubin < 2.5 mg/dL
    3. INR < 1.5 and aPTT < 1.5 x ULN
    4. Hemoglobin > 9 g/dL
    5. Platelet count > 100 x 10E9/L
    6. WBC > 3 x 10E9/L
    7. ANC > 1.5 x 10E9/L (or WBC > 3.0 x 10E9/L)

Exclusion Criteria:

  • Patient unable or not willing to comply with the protocol regulations.
  • The investigator deems it necessary to surgically (re-)resect the present tumor (NOTE: the patient might still be eligible for randomization at a later timepoint).
  • Tumor surgery, tumor debulking, or other neurosurgery within 3 months prior to randomization. If a ≤48-hour routine post-surgery MRI (in accordance with study specifications) qualifies the patient for study participation, the patient can be randomized 30 ± 7 days post-surgery.
  • Radiotherapy or stereotactic (gamma knife) radiosurgery within 3 months prior to randomization.
  • Prior interstitial brachytherapy of the brain with permanent implants. Prior interstitial brachytherapy of the brain with removable implants within 3 months prior to randomization.
  • Chemotherapy, hormone therapy, or any other therapy with established or suggested anti-tumor effects within 4 weeks (nitrosoureas: 6 weeks) prior to randomization.
  • Prior anti-TGF-beta 2 targeted therapy.
  • Screening MRI shows a mass effect caused by the tumor defined as significant compression of the ventricular system and/or a midline shift (≥ 3 mm, central MRI review). Compression of the ventricular system and/or a midline shift ≥ 3 mm only due to the presence of (a) cyst(s) or scarring processes does not exclude an individual from the study.
  • Participation in another clinical study with another investigational medicinal product within 30 days prior to randomization.
  • History of a second independent malignant disorder within 5 years, except for carcinoma in situ of the cervix and basal cell carcinoma.
  • Presence of poorly controlled seizures.
  • Clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure, unstable angina, or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to randomization.
  • Known HIV, HBV or HCV infection.
  • Acute viral, bacterial, or fungal infection.
  • Acute medical problems that may be considered to become an unacceptable risk, or any conditions, which might be contraindications for starting study treatment.
  • Presence of high risk for pulmonary toxicities, defined as:

    1. Lung function: vital capacity ≤ 70%
    2. Status following sequential or concomitant thoracic irradiation
    3. Increased risk for a pulmonary toxicity induced by BCNU (Carmustine) or CCNU (Lomustine). Risk factors include smoking, presence of a respiratory condition, pre-existing radiographic pulmonary abnormalities, exposure to agents that cause lung damage.
  • History of allergies to reagents used in this study, history of celiac disease.
  • Drug abuse or extensive use of alcohol.
  • Clinically relevant psychiatric disorders / legal incapacity or a limited legal capacity.
  • Concomitant treatment with yellow fever vaccine.
18 Years to 70 Years
Contact information is only displayed when the study is recruiting subjects
United States,   Argentina,   Austria,   Brazil,   Canada,   France,   Germany,   Hungary,   India,   Korea, Republic of,   Mexico,   Poland,   Russian Federation,   Spain,   Taiwan,   United Kingdom
AP 12009-G005
Isarna Therapeutics GmbH
Isarna Therapeutics GmbH
Not Provided
Study Chair: Rolando Del Maestro, MD, PhD Montreal Neurological Institute and Hospital
Isarna Therapeutics GmbH
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP